Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy

Published:October 25, 2018DOI:


      Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic diseases and malignancies. The interleukin family has been critically associated with progression of atherosclerosis, insulin resistance, and various malignancies. Given the advent of pharmacologic interleukin-1 (IL-1) inhibition, this pathway can potentially be targeted to improve outcomes. In the recently concluded Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, investigators looked at the potential role of IL-1 (especially IL-1β) inhibition in halting the progression of atherosclerosis. In the subset analysis of the data from this trial, IL-1β inhibition with canakinumab was found to have beneficial effects in other cardiometabolic diseases characterized by inflammation, like diabetes, stroke, and chronic kidney disease, and also in patients with lung cancer. In this article, we will try to review the current literature on the role of canakinumab in the treatment of cardiometabolic diseases and malignancies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ballak D
        • Stienstra R
        • Tack C
        • Dinarello C
        • Van diepen J
        IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance.
        Cytokine. 2015; 75: 280-290
        • Benjamin E
        • Blaha M
        • Chiuve S
        • et al.
        Heart Disease and Stroke Statistics–2017 update: a report from the American Heart Association.
        Circulation. 2017; 135: e146-e603
        • Castro J
        • El-Atat F
        • McFarlane S
        • Aneja A
        • Sowers J
        Cardiometabolic syndrome: pathophysiology and treatment.
        Curr Hypertens Rep. 2003; 5: 393-401
        Date accessed: January 12, 2018
        • Ridker P
        • Everett B
        • Thuren T
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Liberale L
        • Diaz-Cañestro C
        • Bonetti N
        • et al.
        Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke.
        Eur Heart J. 2018; 39: 3511-3517
        • Everett B
        • Donath M
        • Pradhan A
        • et al.
        Anti-nflammatory therapy with canakinumab for the prevention and management of diabetes.
        J Am Coll Cardiol. 2018; 71: 2392-2401
        • Ridker P
        • MacFadyen J
        • Glynn R
        • et al.
        Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease.
        J Am Coll Cardiol. 2018; 71: 2405-2414
        • Dinarello C
        Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
        Blood. 2011; 117: 3720-3732
        • Dinarello C
        • Simon A
        • Van der Meer J
        Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
        Nat Rev Drug Discov. 2012; 11: 633-652
        • Murray KN
        • Parry-Jones AR
        • Allan SM
        Interleukin-1 and acute brain injury.
        Front Cell Neurosci. 2015; 9: 18
        • Jo EK
        • Kim JK
        • Shin DM
        • Sasakawa C
        Molecular mechanisms regulating NLRP3 inflammasome activation.
        Cell Mol Immunol. 2016; 13: 148-159
        • Chakraborty A
        • Tannenbaum S
        • Rordorf C
        • et al.
        Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
        Clin Pharmacokinet. 2012; 51: e1-e18
        • Anumolu SS
        • Lindgren S
        • Vemula J
        • et al.
        Bioequivalence of canakinumab injected subcutaneously via an autoinjector device or a prefilled safety syringe device in healthy subjects.
        Clin Pharmacol Drug Dev. 2018; 7: 829-836
        • Sota J
        • Vitale A
        • Insalaco A
        • et al.
        Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study [e-pub ahead of print].
        Clin Rheumatol. 2018;
        • U.S. Food and Drug Administration
        FDA approves expanded indications for Ilaris for three rare diseases 2016 May 17.
        (Available at:)
        • Libby P
        • Ordovas JM
        • Auger KR
        • Robbins AH
        • Birinyi LK
        • Dinarello CA
        Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.
        Am J Pathol. 1986; 124: 179-185
        • Gimbrone M
        • García-Cardeña G
        Endothelial cell dysfunction and the pathobiology of atherosclerosis.
        Circ Res. 2016; 118: 620-636
        • Kirii H
        • Niwa T
        • Yamada Y
        • et al.
        Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice.
        Arterioscler Thromb Vasc Biol. 2003; 23: 656-660
        • Shimokawa H
        • Ito A
        • Fukumoto Y
        • et al.
        Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor.
        J Clin Invest. 1996; 97: 769-776
        • Gomez D
        • Baylis R
        • Durgin B
        • et al.
        Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice.
        Nat Med. 2018; 24: 1418-1429
        • Choudhury R
        • Birks J
        • Mani V
        • et al.
        Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance.
        J Am Coll Cardiol. 2016; 68: 1769-1780
      1.; National Library of Medicine. Identifier NCT01731990. Safety, tolerability and efficacy of ACZ885 on leg artery structure in patients with peripheral artery disease. Available at: Accessed September 19, 2018.

        • Sahebkar A
        • Di Giosia P
        • Stamerra C
        • et al.
        Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms.
        Br J Clin Pharmacol. 2016; 81: 1175-1190
        • Sota J
        • Vitale A
        • Rigante D
        • Cantarini L
        Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study [e-pub ahead of print].
        Clin Rheumatol. 2018;
        • Pradhan AD
        • Manson JE
        • Rifai N
        • Buring JE
        • Ridker PM
        C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
        JAMA. 2001; 286: 327-334
        • Donath MY.
        Targeting inflammation in the treatment of type 2 diabetes: time to start.
        Nat Rev Drug Discov. 2014; 13: 465-476
        • DiK B
        • Bahcivan E
        • Eser Faki H
        • Uney K
        Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats.
        Can J Physiol Pharmacol. 2018; 96: 751-756
        • Larsen C
        • Faulenbach M
        • Vaag A
        • et al.
        Interleukin-1–receptor antagonist in type 2 diabetes mellitus.
        N Engl J Med. 2007; 356: 1517-1526
        • Rissanen A
        • Howard C
        • Botha J
        • Thuren T
        Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
        Diabetes Obes Metab. 2012; 14: 1088-1096
        • Hensen J
        • Howard C
        • Walter V
        • Thuren T
        Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial.
        Diabetes Metab. 2013; 39: 524-531
        • Ridker P
        • Howard C
        • Walter V
        • et al.
        Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
        Circulation. 2012; 126: 2739-2748
        • Dominguez H
        • Storgaard H
        • Rask-Madsen C
        • et al.
        Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes.
        J Vasc Res. 2005; 42: 517-525
        • Bernstein LE
        • Berry J
        • Kim S
        • Canavan B
        • Grinspoon SK
        Effects of etanercept in patients with the metabolic syndrome.
        Arch Intern Med. 2006; 166: 902-908
        • Barzilay J
        • Jablonski K
        • Fonseca V
        • et al.
        The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
        Diabetes Care. 2013; 37: 1083-1091
        • Goldfine AB
        • Fonseca V
        • Jablonski KA
        • et al.
        The effects of salsalate on glycemic control in patients with type 2 diabetes.
        Ann Intern Med. 2010; 152: 346-357
        • Fox C
        • Matsushita K
        • Woodward M
        • et al.
        Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.
        Lancet. 2012; 380: 1662-1673
        • Dungey M
        • Hull K
        • Smith A
        • Burton J
        • Bishop N
        Inflammatory factors and exercise in chronic kidney disease.
        Int J Endocrinol. 2013; 2013569831
        • Hutton HL
        • Ooi JD
        • Holdsworth SR
        • Kitching AR
        The NLRP3 inflammasome in kidney disease and autoimmunity.
        Nephrology (Carlton). 2016; 21: 736-744
        • Nowak K
        • Chonchol M
        • Ikizler T
        • et al.
        IL-1 inhibition and vascular function in CKD.
        J Am Soc Nephrol. 2017; 28: 971-980
        • Shalapour S
        • Karin M
        Immunity, inflammation, and cancer: an eternal fight between good and evil.
        J Clin Invest. 2015; 125: 3347-3355
        • Voronov E
        • Shouval DS
        • Krelin Y
        • et al.
        IL-1 is required for tumor invasiveness and angiogenesis.
        Proc Natl Acad Sci U S A. 2003; 100: 2645-2650
        • Lewis AM
        • Varghese S
        • Xu H
        • Alexander HR
        Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.
        J Transl Med. 2006; 4: 48
        • Yu A
        • Wang Y
        • Bian Y
        • et al.
        IL-1β promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway.
        J Cell Biochem. 2018; 119: 8163-8173
        • Cui G
        • Yuan A
        • Sun Z
        • Zheng W
        • Pang Z
        IL-1β/IL-6 network in the tumor microenvironment of human colorectal cancer.
        Pathol Res Pract. 2018; 214: 986-992
        • O'Callaghan DS
        • O'Donnell D
        • O'Connell F
        • O'Byrne KJ
        The role of inflammation in the pathogenesis of non-small cell lung cancer.
        J Thorac Oncol. 2010; 5: 2024-2036
        • Ridker PM
        • MacFadyen JG
        • Thuren T
        • et al.
        Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
        Lancet. 2017; 390: 1833-1842
        • Hong DS
        • Hui D
        • Bruera E
        • et al.
        MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
        Lancet Oncol. 2014; 15: 656-666
        • Lust JA
        • Lacy MQ
        • Zeldenrust SR
        • et al.
        Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
        Mayo Clin Proc. 2009; 84: 114-122
        • Everett BM
        • Pradhan AD
        • Solomon DH
        • et al.
        Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
        Am Heart J. 2013; 166: 199-207.e15